The U.S. Preventive Services Task Force makes recommendations for preventive services—including Gilead’s twice-yearly HIV ...

Under PreCheck, the FDA will communicate more frequently with pharmaceutical companies, helping them as they establish or ...

Strand Therapeutics' lead asset is STX-001, an intra-tumor self-replicating mRNA therapy that carries a payload expressing ...

Eli Lilly’s orforglipron cut body weight to a lesser extent than rival Novo Nordisk’s semaglutide, falling into analysts’ ...

Arguably the FDA’s most anticipated decision this month is for a subcutaneous induction formulation of Biogen and Eisai’s ...

From the price of forthcoming weight loss pill orforglipron, to Most Favored Nation drug pricing and the market battle with ...

The German giant has already trimmed more than 10,000 employees since initiating a massive restructuring initiative in July ...

Higher competition for fewer roles remains the status quo for biopharma professionals, based on BioSpace data. Additionally, ...

In this episode presented by Cresset, BioSpace’s head of insights Lori Ellis discusses the emerging geopolitical battle for ...

In December 2024, Dewpoint Therapeutics CEO Ameet Nathwani said the biotech’s cash runway would last until the third quarter of 2025.

Terns, once a rising star in obesity and the MASH space, will refocus on cancer and partner out a handful of obesity assets.

The Department of Health and Human Services is terminating around $500 million in BARDA contracts associated with mRNA ...